Structures by: Hübschle C. B.
Total: 22
C15H21N3O5,2(H2O),0.634(H2O)
C15H21N3O5,2(H2O),0.634(H2O)
Organic & biomolecular chemistry (2006) 4, 17 3242-3251
a=8.121Å b=9.299Å c=12.532Å
α=90.00° β=91.21° γ=90.00°
Ofloxcacin
C18H20FN3O4
CrystEngComm (2012) 14, 7 2520
a=30.073(6)Å b=6.7129(14)Å c=16.722(3)Å
α=90.00° β=104.76(3)° γ=90.00°
Norfloxacin
C16H18FN3O3,2(H2O)
CrystEngComm (2012) 14, 7 2520
a=8.2477(6)Å b=21.6745(17)Å c=9.5199(7)Å
α=90.00° β=110.6920(10)° γ=90.00°
Norfloxacin
C16H18FN3O3
CrystEngComm (2012) 14, 7 2520
a=4.2600(6)Å b=9.7217(12)Å c=17.862(3)Å
α=78.225(8)° β=87.712(9)° γ=79.626(7)°
Enoxacin
C15FN4O3H17,1.72(H2O)
CrystEngComm (2012) 14, 7 2520
a=8.4124(6)Å b=22.0645(15)Å c=17.1587(12)Å
α=90.00° β=100.8960(10)° γ=90.00°
Lomefloxacin
C17H20F2N3O3,2(H2O),0.95(Cl)
CrystEngComm (2012) 14, 7 2520
a=5.2000(10)Å b=39.960(8)Å c=9.3800(19)Å
α=90.00° β=90.55(3)° γ=90.00°
C15H21N3O5,C2H6O
C15H21N3O5,C2H6O
Organic & biomolecular chemistry (2006) 4, 17 3242-3251
a=8.845Å b=9.0567Å c=12.3638Å
α=90.000° β=94.563° γ=90.000°
C72F36
C72F36
Chemical communications (Cambridge, England) (2007) 39 4003-4005
a=20.720(3)Å b=20.720(3)Å c=9.729(2)Å
α=90.00° β=90.00° γ=120.00°
4-Methyl-3-[(tetrahydro-2H-pyran-2-yl) oxy] thiazole-2(3H)-thione
C9H13NO2S2
Acta Crystallographica Section B (2020) 76, 3
a=9.81060(10)Å b=10.53450(10)Å c=10.43120(10)Å
α=90° β=91.7870(10)° γ=90°
Bergenin
C14H16O9,H2O
Acta Crystallographica Section B (2009) 65, 6 749-756
a=7.4880(10)Å b=13.9340(10)Å c=14.2750(10)Å
α=90.° β=90.° γ=90.°
C52H52O10
C52H52O10
Acta Crystallographica, Section B (2006) 62, 4 843-849
a=11.9602(3)Å b=18.6249(5)Å c=19.9648(5)Å
α=90° β=90° γ=90°
O,O-Dimethylalpinumisoflavone
C22H20O5
Acta Crystallographica, Section B (2006) 62, 4 843-849
a=9.0604(7)Å b=19.0147(14)Å c=10.5963(8)Å
α=90° β=101.333(2)° γ=90°
4-O-Methylalpinumisoflavone
C21H18O5
Acta Crystallographica, Section B (2006) 62, 4 843-849
a=8.3670(2)Å b=8.4724(2)Å c=23.6852(5)Å
α=90.00° β=92.5140(10)° γ=90.00°
Thymidine
C10H14N2O5
Acta Crystallographica Section B (2008) 64, 3 363-374
a=4.8462(19)Å b=13.901(6)Å c=16.316(7)Å
α=90.0° β=90.0° γ=90.0°
1-cyclopropyl-6-fiuoro-4-oxo-7-(1-piperazinyl)- 1,4-dihydroquinoline-3-carboxylic acid) 1.4hydrate hydrochloride
C17H19FN3O3,1.4(H2O),Cl
Journal of Applied Crystallography (2009) 42, 6 1110-1121
a=12.872(1)Å b=19.576(1)Å c=6.948(1)Å
α=90.0(0)° β=90.55(5)° γ=90.0(0)°
1-cyclopropyl-6-fiuoro-4-oxo-7-(1-piperazinyl)- 1,4-dihydroquinoline-3-carboxylic acid) hexahydrate
C17H18FN3O3,6(H2O)
Journal of Applied Crystallography (2009) 42, 6 1110-1121
a=9.5070(1)Å b=9.9649(1)Å c=11.0233(1)Å
α=94.182(1)° β=100.118(1)° γ=91.432(1)°
L-Homoserine
C4H9NO3
Acta Crystallographica Section A (2012) 68, 4 435-442
a=9.1735(1)Å b=11.4736(2)Å c=5.4171(1)Å
α=90.0° β=90.0° γ=90.0°
L-Tryptophan formic acid solvate
C11H12N2O2,CH2O2
Acta Crystallographica Section C (2002) 58, 9 o540-o542
a=5.3163(3)Å b=8.1348(4)Å c=27.259(2)Å
α=90° β=90° γ=90°
D,L-Serine
C3H7NO3
Acta Crystallographica Section A Foundations of Crystallography (2005) 61, 3 314-320
a=10.7355(9)Å b=9.1456(7)Å c=4.8304(4)Å
α=90° β=106.460(10)° γ=90°
D,L-Serine
C3H7NO3
Acta Crystallographica Section A Foundations of Crystallography (2005) 61, 3 314-320
a=10.7621(10)Å b=9.1771(9)Å c=4.7883(5)Å
α=90° β=106.76(2)° γ=90°
D,L-Serine
C3H7NO3
Acta Crystallographica Section A Foundations of Crystallography (2005) 61, 3 314-320
a=10.7764(10)Å b=9.1947(9)Å c=4.7788(5)Å
α=90° β=106.87(2)° γ=90°
Tetraborane
B4H10
Inorganic Chemistry (2008) 47, 1874-1876
a=5.7890(16)Å b=10.135(3)Å c=8.690(2)Å
α=90.00° β=106.037(6)° γ=90.00°